Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...

For the next 15 years, biopharmaceutical firm Incyte Corp. will lease the former John Wanamaker building on Augustine Cut-off ...

About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical suspicion of primary care clinicians. The need to treat asymptomatic or minimally ...

GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

Many investors continue to be worried about Incyte’s financial prospects when the patent for the company’s blood cancer ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

What do you think is worth looking out for in the future for myelofibrosis? I thought we could focus first on non–drug-related research that is needed to move the field forward. What do you ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced abstracts detailing selinexor data have been selected to be ...

Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...

The proceeds are expected to enable us to support the commercial launch of RYTELO in the U.S. and potential launch in the EU, ...

GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...